L’Oréal wins dismissal of BP acne lawsuit
The Benzene Battle: Why L’Oréal Won a Major Lawsuit Over Acne Products
In a significant legal move that shifts the balance between consumer claims and federal regulation, a US federal judge has dismissed a major lawsuit against L’Oréal USA. The case centered on allegations that certain acne products, sold under the company’s popular CeraVe and La Roche-Posay brands, contained or could degrade into benzene.
The litigation brought forward serious claims from consumers, alleging that these products were misbranded and adulterated. Plaintiffs argued that the presence or potential formation of benzene in these cosmetics constituted deceptive business practices, breach of implied warranty, and other legal violations.
Specifically, the lawsuits targeted popular items such as the CeraVe Acne Foam Cream Cleanser, the CeraVe Acne Foaming Cream Wash, and the La Roche-Posay Effaclar Duo Dual Acne Treatment. The core of the dispute was whether the use of benzoyl peroxide in these formulations, and the potential risk of benzene formation, violated consumer protection laws.
When faced with these claims, the legal battle turned to the realm of federal oversight. The US District Court for the Southern District of New York ultimately ruled that L’Oréal complied with all relevant federal labeling requirements. The court also noted that the Food and Drug Administration’s (FDA) acne monograph permits the use of benzoyl peroxide without requiring a benzene warning, effectively putting the federal regulatory framework ahead of the plaintiffs’ state-law claims.
Furthermore, the court rejected the plaintiffs’ argument that federal law establishes a binding limit of 2 ppm for benzene in these products. This decision underscored the primacy of federal cosmetic safety standards in this dispute.
The dismissal of the case with prejudice means that the plaintiffs were denied the opportunity to amend their complaint, effectively closing the door on their claims regarding product adulteration based on benzene. This ruling significantly strengthens the position of cosmetic and Over-The-Counter (OTC) acne product manufacturers facing similar claims.
This outcome highlights a key principle in consumer product law: when federal regulations govern the safety and labeling of a product, they often take precedence over state-level claims. The decision reinforces the existing structure, showing how federal standards can preempt state-law actions when dealing with regulated cosmetic items.
Buy on Amazon
Credit
